LXY6090 – a novel manassantin a derivative – limits breast cancer growth through hypoxia-inducible factor-1 inhibition

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 3829-3840

  Lai, Fangfang ^a   Liu, Qian ^b   Liu, Xiaoyu ^a   Ji, Ming ^a   Xie, Ping ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Antitumor; Breast cancer; Hypoxia inducible factor 1; LXY6090; Manassantin A derivative

Indexed keywords

CYCLOPENTANE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LXY 6090; PACLITAXEL; PLANT EXTRACT; SOMATOMEDIN B; TETRAHYDROFURAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG STRUCTURE; FEMALE; GENE; HUMAN; HUMAN CELL; IGF2 GENE; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SAURURUS CERNUUS; TUMOR VOLUME; TUMOR XENOGRAFT; VEGF GENE;

EID: 84976300002     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S106925     Document Type: Article

References (35)

1. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl). 2007;85(12):1301–1307.
2. Chiche J, Ricci JE, Pouysségur J. Tumor hypoxia and metabolism – towards novel anticancer approaches. Ann Endocrinol (Paris). 2013; 74(2):111–114.
3. Brahimi-Horn MC, Pouysségur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol. 2005; 242:157–213.
4. Kaelin WG Jr. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol. 2011;76:335–345.
5. Mimeault M, Batra SK. Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev. 2014;23(2): 234–254.
6. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–1237.
7. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510–5514.
8. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–468.
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.
10. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev. 2003; 17(21):2614–2623.
11. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997;272(36):22642–22647.
12. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000;14(16):1983–1991.
13. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29(4):297–307.
14. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009;13(9A):2780–2786.
15. Ward C, Langdon SP, Mullen P, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev. 2013;39(2):171–179.
16. Kwon DY, Lee HE, Weitzel DH, et al. Synthesis and biological evaluation of manassantin analogues for hypoxia-inducible factor 1alpha inhibition. J Med Chem. 2015;58(19):7659–7671.
17. Hodges TW, Hossain CF, Kim YP, Zhou YD, Nagle DG. Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J Nat Prod. 2004;67(5):767–771.
18. Hossain CF, Kim YP, Baerson SR, et al. Saururus cernuus lignans – potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2005;333(3):1026–1033.
19. Kasper AC, Moon EJ, Hu X, et al. Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. Bioorg Med Chem Lett. 2009;19(14):3783–3786.
20. Minegishi H, Matsukawa T, Nakamura H. Synthesis and biological evaluation of diaryl-substituted carboranes as inhibitors of hypoxia inducible factor (HIF)-1 transcriptional activity. ChemMedChem. 2013; 8(2):265–271.
21. Rao KV, Puri VN, Diwan PK, Alvarez FM. Preliminary evaluation of manassantin A, a potential neuroleptic agent from Saururus cernuus. Pharmacol Res Commun. 1987;19(9):629–638.
22. Lai FF, Liu XY, Niu F, Lang LW, Xie P, Chen XG. [A novel HIF-1 inhibitor – manassantin A derivative LXY6099 inhibits tumor growth]. Yao Xue Xue Bao. 2014;49(5):622–626. Chinese.
23. Lang L, Liu X, Li Y, et al. A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth. PLoS One. 2014;9(6):99584.
24. Lang L, Tang K, Li Y, Liu X, Wang C, Chen X. [Identification of two small molecule inhibitors of hypoxia-inducible factor 1 with different cell-based screening model]. Zhongguo Zhong Yao Za Zhi. 2012; 37(14):2151–2155. Chinese.
25. Lai F, Madan N, Ye Q, et al. Identification of a mutant alpha1 Na/K-ATPase that pumps but is defective in signal transduction. J Biol Chem. 2013;288(19):13295–13304.
26. Niu F, Li Y, Lai FF, et al. LB-1 exerts antitumor activity in pancreatic cancer by inhibiting HIF-1alpha and Stat3 signaling. J Cell Physiol. 2015;230(9):2212–2223.
27. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010; 70(3):1063–1071.
28. Sun HL, Liu YN, Huang YT, et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene. 2007;26(27): 3941–3951.
29. Cao Z, Fang J, Xia C, Shi X, Jiang BH. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res. 2004; 10(15):5253–5263.
30. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther. 2006;5(5): 1227–1238.
31. Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res. 2001;264(1):117–125.
32. Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life. 2001;52(1–2):43–47.
33. Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–389.
34. Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013;9(11):1623–1636.
35. Li J, Zhao K, Wang F, Cai J, Li Z, Zou L. X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo. Mol Med Rep. 2015;12(2):3115–3120.